Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
MM-520 Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bo... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
MM-520 Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Results From the CC-92480-MM-002 Trial
0
Authors
Albert Oriol
19 more
Albert Oriol
•
Irwindeep Sandhu
17 more
•
Paul Katz
Published
September 1, 2024
Paper
Conversation
0
Reviews
0
Bounties
0
Abstract
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Clinical Lymphoma Myeloma & Leukemia
Topics
Physics
Cancer Oncology
Medicine
Internal Medicine
Hematology
Show all topics
DOI
10.1016/s2152-2650(24)01697-5
